Layer-specific myocardial strain for early detection of anthracycline-induced cardiotoxicity: the CARDIAC-STRAIN prospective diagnostic study protocol
Clicks: 1
ID: 323387
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #72 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Anthracyclines remain cornerstone agents in oncology, yet their cardiotoxic potential poses a substantial clinical challenge. Up to 30% of treated patients develop some degree of cardiac dysfunction, with overt heart failure occurring in 2–5% of cases. Current surveillance relies on serial ejection fraction measurements, which detect damage only after significant myocardial injury has occurred. Histopathological evidence consistently shows that the subendocardial layer suffers earliest and most severely from anthracycline exposure—often weeks before any decline in global ventricular function becomes apparent. This temporal gap represents a missed opportunity for timely cardioprotective intervention. Purpose We designed the CARDIAC-STRAIN study to determine whether layer-specific strain analysis by cardiac magnetic resonance can identify subclinical cardiotoxicity substantially earlier than conventional echocardiographic surveillance, potentially enabling earlier initiation of cardioprotective treatment. Methods This prospective single-centre diagnostic cohort study will recruit 120 consecutive patients scheduled for anthracycline-based chemotherapy (sample size calculated to detect 20% sensitivity difference, power 80%, α=0.05). Eligible participants are aged 18–75 years with preserved baseline ejection fraction (≥50%) and no prior anthracycline exposure or known cardiomyopathy. Each patient undergoes blinded comprehensive cardiac evaluation at four timepoints: baseline, after the fourth chemotherapy cycle, four weeks post-treatment, and at six months' follow-up. The protocol includes 1.5T cardiac MRI with cine sequences, native and post-contrast T1 mapping, T2 mapping, and late gadolinium enhancement. Layer-specific strain is quantified at subendocardial, midmyocardial, and subepicardial levels using dedicated feature-tracking software. Parallel assessments include three-dimensional echocardiography and cardiac biomarkers (troponin, NT-proBNP). Primary endpoints: ejection fraction decline >10% to below 50%, decline >15% with preserved function, or layer-specific strain deterioration >15% from baseline. Study hypothesis: We hypothesize that layer-specific strain analysis will detect subclinical myocardial injury approximately 2–4 weeks earlier than conventional ejection fraction monitoring, with significantly improved diagnostic sensitivity compared to standard surveillance protocols. Expected outcomes: If layer-specific strain analysis proves capable of reliably identifying subclinical cardiotoxicity before irreversible damage occurs, this approach may help shift clinical practice from heart failure treatment to early prevention in cardio-oncology. The study received ethics committee approval in November 2025, and patient recruitment is underway.
| Reference Key |
openalex_W7172244648
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | N Kavelashvili, N Sharashidze, F Schiedat, A Kloppe |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.066
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.